What's Going On With MindMed And Psychedelic Stocks?
What's Going On With MindMed And Psychedelic Stocks?
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) shares are trading lower Wednesday after a Food and Drug Administration (FDA) panel rejected the approval of MDMA therapy for people with post-traumatic stress disorder (PTSD).
周三，Mind Medicine（MindMed）股票（NASDAQ：MNMD）因食品和药物管理局（FDA）小组拒绝PTSD患者使用MDMA疗法而下跌。
The Details:
细节：
MindMed and other psychedelic stocks, including ATAI Life Sciences N.V (NASDAQ:ATAI) and COMPASS Pathways Plc (NASDAQ:CMPS), are down after an FDA panel rejected the use of MDMA-assisted therapy for PTSD on Tuesday.
周二，ATAI Life Sciences N.V（NASDAQ：ATAI）和COMPASS Pathways Plc（NASDAQ：CMPS）等MindMed和其他迷幻股票在FDA小组拒绝使用MDMA辅助治疗PTSD后下跌。
The FDA panel voted 9 to 2 on whether the MDMA-assisted therapy was effective and 10 to 1 on whether the proposed treatment's benefits outweighed its risks. Members of the panel expressed concerns about the designs of the two studies submitted by Lykos Therapeutics, including study participants correctly identifying MDMA versus the placebo.
FDA小组投票表决，对于MDMA辅助治疗是否有效，投票表决为9:2；对于所提出治疗的益处是否大于其风险，投票表决为10:1。小组成员对Lykos Therapeutics提交的两项研究的设计表达了担忧，其中包括研究参与者正确鉴别MDMA与安慰剂的问题。
The FDA's rejection of the Lykos Therapeutics drug highlights the regulatory issues faced by companies developing psychedelic therapies and treatments.
FDA拒绝Lykos Therapeutics药物突显了开发迷幻疗法和治疗的公司面临的监管问题。
Related News: Wedbush's Dan Ives Says WWDC 2024 Is 'Most Important Event For Apple In Over A Decade': What To Expect
相关资讯：Wedbush的丹•艾夫斯表示，2024年的WWDC是苹果公司十年来最重要的活动：预期会发生什么
Will MNMD Stock Go Up?
MNMD股票会上涨吗?
When trying to assess whether or not Mind Medicine will trade higher from current levels, it's a good idea to take a look at analyst forecasts.
当试图评估Mind Medicine股票是否会从当前水平上升时，建议查看分析师预测。
Wall Street analysts have an average 12-month price target of $33.75 on Mind Medicine. The Street high target is currently at $75 and the Street low target is $20. Of all the analysts covering Mind Medicine, 8 have positive ratings, no one has neutral ratings and no one has negative ratings.
华尔街分析师在Mind Medicine股票上的平均12个月价格目标为33.75美元。目标最高价为目前的75美元，最低点为20美元。在所有涉及Mind Medicine股票的分析师中，有8个持有正面评级，没有人持有中立评级，也没有人持有负面评级。
In the last month, 4 analysts have adjusted price targets. Here's a look at recent price target changes [Analyst Ratings]. Benzinga also tracks Wall Street's most accurate analysts. Check out how analysts covering Mind Medicine have performed in recent history.
在过去的一个月中，有4个分析师调整了价格目标。以下是最近价格目标变化的情况[分析师评级]。Benzinga还追踪华尔街最准确的分析师。查看覆盖Mind Medicine的分析师在最近的历史中表现如何。
Stocks don't move in a straight line. The average stock market return is approximately 10% per year. Mind Medicine is 86.33% up year-to-date. The average analyst price target suggests the stock could have further upside ahead.
股票市场的波动是成正比例的，Mind Medicine股票年度上涨了86.33%。分析师的平均价格目标表明，该股票未来仍有上涨空间。
For a broad overview of everything you need to know about Mind Medicine, visit here. If you want to go above and beyond, there's no better tool to help you do just that than Benzinga Pro. Start your free trial today.
如果您想了解Mind Medicine的所有内容，请访问此处。如果您希望超越所需，那么没有比Benzinga Pro更好的工具来帮助您做到这一点。立即开始您的免费试用。
MNMD, ATAI, CMPS Price Action: According to Benzinga Pro, MindMed shares are down 15% at $7.00, Atai Life Sciences shares are down 6.55% at $1.43 and Compass Pathways shares are down 11.5% at $6.78 at the time of publication Wednesday.
根据Benzinga Pro的消息，在周三发行的文章中，MindMed股票下跌15%，达到7.00美元；Atai Life Sciences股票下跌6.55%，以1.43美元交易；Compass Pathways股票下跌11.5%，以6.78美元交易。MNMD，ATAI，CMPS价格行动。
Image: Shutterstock
图片：shutterstock